Rodger Novak President and Chair of the Board of Directors CRISPR Therapeutics
Dr. Rodger Novak is a serial entrepreneur and experienced pharmaceutical and biotechnology executive who co-founded CRISPR Therapeutics in late 2013 in Basel, Switzerland, and led the company as CEO until December 2017.
Contact options for Rodger Novak
Dr. Novak now serves the company as President and Chair of the Board of Directors. He is also a Director on the Board of Casebia Therapeutics, CRISPR’s 50-50 joint venture with Bayer AG.
During his four years as CEO he built the Cambridge, USA, based operations with now more than 150 employees and turned the company from a research organization into a clinical stage company. Dr. Novak also managed to assemble a highly competitive and experienced management team comprising senior biotech and pharma executives. Under his leadership, the company raised more than USD 400 million in capital, closed a multi-billion USD deal with Vertex Pharmaceuticals and established a joint-venture with Bayer worth north of USD 600 million.
CRISPR Therapeutics successfully listed at NASDAQ in October 2016, with a current market capitalization of about USD 3 billion. Before CRISPR Therapeutics Dr. Novak was Global Head Infectious Diseases, R&D, with Sanofi in Paris, France, where he was responsible for the discovery, research and development, including late stage clinical development, of antibiotics, antivirals, and drugs for the diseases of the developing world.
In early 2006 Dr. Novak founded Nabriva Therapeutics, an antibacterial development company in Vienna, Austria. Nabriva is a spin-out from Sandoz/Novartis, where Dr. Novak served as Vice-Head of the Antibiotic Research Institute. Dr. Novak was the company’s COO for 5 years, primarily responsible for the development of their key assets, today clinical phase III stage drugs. Nabriva Therapeutics is a public company also listed at NASDAQ.
Dr. Novak received his MD in Germany in 1993 and his medical license for the USA in
1994. He was a postdoctoral fellow at The Rockefeller University, St Jude Children’s
Research Hospital and the Skirball Institute, NYU, USA. In 2001, he was appointed as
tenured Associate Professor for Microbiology at the Vienna Biocenter, Austria. Dr.
Novak authored numerous publications, among them articles in Nature, Nature
Medicine and Molecular Cell and is co-inventor of several patents